Developer docs
API playgroundTry for free, no card

Search company profiles

Prapela

Full company profile

uuid0002p28

Namestring
Prapela
Legal namestring
Prapela
Websiteurl
prapela.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Prapela is a privately held medical device company founded in 2017 and based in Biddeford, Maine. The company has developed the SVS Bassinet Pad, a hardware device that delivers Stochastic Vibro-tactile Stimulation (SVS) — a continuous, randomized pattern of low-level vibrations designed to console and stabilize infants, particularly those exposed to opioids in utero and diagnosed with Neonatal Abstinence Syndrome (NOWS). The technology is clinically validated to console opioid-exposed newborns as effectively as human holding and is intended to operate continuously alongside caregiver protocols within established NOWS scoring frameworks (ESC, Finnegan, or hybrid systems).

The company's go-to-market is enterprise-focused, targeting hospital neonatal intensive care units (NICUs) and maternity wards through a clinical-evidence-based direct sales motion aimed at hospital procurement and clinical decision-makers. The SVS Bassinet Pad received FDA De Novo authorization (DEN240031) on April 4, 2025, establishing the device as a regulated Class II medical device for the specific indication of opioid-exposed newborns. Pricing is not publicly disclosed, and no customers, revenue figures, or distribution partnerships are reported in the available source material.

Prapela has been funded primarily through non-dilutive sources, accumulating approximately $8.2M across grants from the National Institutes of Health (including NIDA), the Charles Hood Foundation, state-level economic development agencies (Ohio Third Frontier, Massachusetts Life Sciences Center, Maine Technology Institute, Southern Maine Planning and Development Commission), and corporate/philanthropic sources including Johnson & Johnson and MassChallenge. The company employs between 1 and 10 people and operates with a small leadership team consisting of CEO and co-founder John Konsin, co-founder and technical advisor Jim Niemi, and VP of Product Development David Morrill.

Short descriptiontext

Prapela is a Biddeford, Maine medical device company that has developed the FDA De Novo-authorized SVS Bassinet Pad, delivering Stochastic Vibro-tactile Stimulation to console opioid-exposed newborns with Neonatal Abstinence Syndrome in hospital NICUs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPortland, United States
HQ citystring
Portland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neonatal medical devices, infant soothing therapy, opioid-exposed newborn care, neonatal abstinence syndrome, hospital neonatal equipment
Industry1 code
PRIMARYHLAFAJAE
Neonatal Intensive Care & Special Care Nurseries (NICU/SCN)
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neonatal Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SVS Bassinet Pad Device Sales
TypeHardware Sales
Description

Medical device revenue from the sale of the SVS bassinet pad system to hospital neonatal units. The device is FDA De Novo authorized for use with opioid-exposed newborns.

prapela.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SVS Bassinet Pad
Description

A breakthrough therapy device utilizing Stochastic Vibro-tactile Stimulation technology to clinically prove to console opioid-exposed newborns as effectively as holding.

prapela.com
Core offering1 text field

Prapela develops and sells the SVS Bassinet Pad, an FDA De Novo authorized medical device that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns and infants with Neonatal Abstinence Syndrome (NOWS). The device operates continuously alongside clinical care teams to stabilize drug-exposed infants as effectively as human holding, while reducing nursing workload in hospital NICU and maternity settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Clinically proven to console opioid-exposed newborns as effectively as holding
+1 more record
Product overview1 text field

Prapela offers a single unified product — the SVS Bassinet Pad — which delivers Stochastic Vibro-tactile Stimulation (SVS) technology to assist drug-exposed infants and other newborns with various health issues. The device is FDA De Novo authorized and clinically proven to reduce costs and improve health outcomes for neonatal abstinence syndrome (NOWS) by providing continuous therapy that consoles infants alongside the care team.

Product and service1 record
1SVS Bassinet Pad
CategoryNeonatal Medical Device
Description

An FDA De Novo authorized medical device pad that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns as effectively as human holding. It works continuously alongside the care team within ESC, Finnegan, or hybrid NOWS management frameworks, reducing nursing burden and improving infant stabilization in hospital NICU and maternity settings.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medical technology company with neonatal pulse oximetry and patient monitoring products sold into hospital NICUs. Comparable in regulatory-cleared, evidence-based neonatal device sales, though focused on monitoring rather than soothing.

TypeBroad incumbent
Description

Established medical device company with a broad neonatal and neurology product portfolio, including NICU screening and monitoring devices. Overlaps with Prapela in serving hospital neonatal units and pursuing regulatory-cleared devices for newborn care.

TypeRegional player
Description

Japanese manufacturer specializing in neonatal and obstetric medical equipment, including incubators and bassinets. Comparable as a focused neonatal medical device vendor, though primarily serving Asia-Pacific markets.

4Drägerwerk
TypeBroad incumbent
Description

Global manufacturer of NICU incubators, warmers, and neonatal respiratory care equipment. Comparable as a hospital-channel medical device vendor addressing neonatal intensive care workflows, though Prapela operates in a far more focused niche.

TypeBroad incumbent
Description

Listed respiratory and neonatal care device company selling infant warming, CPAP, and humidification products into NICUs worldwide. Comparable hospital sales motion and regulatory pathway, but much broader product portfolio.

TypeBroad incumbent
Description

Large incumbent selling NICU incubators, warmers, and patient monitoring into hospitals globally. Comparable as a hospital-channel neonatal device vendor with established GPO contracts.

TypeEmerging player
Description

Manufacturer of neonatal and infant care equipment (incubators, bassinets, phototherapy). Comparable as a focused neonatal medical device maker targeting hospital customers.

TypeBroad incumbent
Description

Major healthcare technology vendor with neonatal monitoring, warming, and NICU informatics offerings. Comparable as a NICU capital equipment competitor with established hospital procurement relationships.

TypeEmerging player
Description

Specialist neonatal medical device company selling ventilators and infant care equipment into NICUs. Comparable as a focused neonatal device vendor with similar hospital sales motion.

TypeEmerging player
Description

Company with neonatal and NICU product lines including feeding support and breast milk solutions sold into hospitals. Partial overlap in NICU channel and newborn care category, though focused on feeding rather than soothing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prapela

Neonatal Medical Devicesprapela.com

Prapela is a Biddeford, Maine medical device company that has developed the FDA De Novo-authorized SVS Bassinet Pad, delivering Stochastic Vibro-tactile Stimulation to console opioid-exposed newborns with Neonatal Abstinence Syndrome in hospital NICUs.

What Prapela does

Prapela is a privately held medical device company founded in 2017 and based in Biddeford, Maine. The company has developed the SVS Bassinet Pad, a hardware device that delivers Stochastic Vibro-tactile Stimulation (SVS) — a continuous, randomized pattern of low-level vibrations designed to console and stabilize infants, particularly those exposed to opioids in utero and diagnosed with Neonatal Abstinence Syndrome (NOWS). The technology is clinically validated to console opioid-exposed newborns as effectively as human holding and is intended to operate continuously alongside caregiver protocols within established NOWS scoring frameworks (ESC, Finnegan, or hybrid systems).

The company's go-to-market is enterprise-focused, targeting hospital neonatal intensive care units (NICUs) and maternity wards through a clinical-evidence-based direct sales motion aimed at hospital procurement and clinical decision-makers. The SVS Bassinet Pad received FDA De Novo authorization (DEN240031) on April 4, 2025, establishing the device as a regulated Class II medical device for the specific indication of opioid-exposed newborns. Pricing is not publicly disclosed, and no customers, revenue figures, or distribution partnerships are reported in the available source material.

Prapela has been funded primarily through non-dilutive sources, accumulating approximately $8.2M across grants from the National Institutes of Health (including NIDA), the Charles Hood Foundation, state-level economic development agencies (Ohio Third Frontier, Massachusetts Life Sciences Center, Maine Technology Institute, Southern Maine Planning and Development Commission), and corporate/philanthropic sources including Johnson & Johnson and MassChallenge. The company employs between 1 and 10 people and operates with a small leadership team consisting of CEO and co-founder John Konsin, co-founder and technical advisor Jim Niemi, and VP of Product Development David Morrill.

Prapela firmographics

Firmographics
Name
Prapela
Legal name
Prapela
Website
https://prapela.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Prapela is a Biddeford, Maine medical device company that has developed the FDA De Novo-authorized SVS Bassinet Pad, delivering Stochastic Vibro-tactile Stimulation to console opioid-exposed newborns with Neonatal Abstinence Syndrome in hospital NICUs.
Ownership category
akta.pro rank

Prapela industry classification

Industry
Product category
Neonatal Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAFAJAE
Neonatal Intensive Care & Special Care Nurseries (NICU/SCN)
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

Keywords

  • Neonatal medical devices
  • Infant soothing therapy
  • Opioid-exposed newborn care
  • Neonatal abstinence syndrome
  • Hospital neonatal equipment

Where Prapela is headquartered

Location

Headquarters

HQ city
Portland
HQ country
United States
HQ region
North America

Markets served

Prapela business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

  1. SVS Bassinet Pad Device Sales: Medical device revenue from the sale of the SVS bassinet pad system to hospital neonatal units. The device is FDA De Novo authorized for use with opioid-exposed newborns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Prapela product offering

Product offering

Core offering

Prapela develops and sells the SVS Bassinet Pad, an FDA De Novo authorized medical device that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns and infants with Neonatal Abstinence Syndrome (NOWS). The device operates continuously alongside clinical care teams to stabilize drug-exposed infants as effectively as human holding, while reducing nursing workload in hospital NICU and maternity settings.

Product overview

Prapela offers a single unified product — the SVS Bassinet Pad — which delivers Stochastic Vibro-tactile Stimulation (SVS) technology to assist drug-exposed infants and other newborns with various health issues. The device is FDA De Novo authorized and clinically proven to reduce costs and improve health outcomes for neonatal abstinence syndrome (NOWS) by providing continuous therapy that consoles infants alongside the care team.

Differentiator

Problem solved

Functional benefit

Brands

  • SVS Bassinet Pad: A breakthrough therapy device utilizing Stochastic Vibro-tactile Stimulation technology to clinically prove to console opioid-exposed newborns as effectively as holding.

Products and services

  • SVS Bassinet Pad An FDA De Novo authorized medical device pad that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns as effectively as human holding. It works continuously alongside the care team within ESC, Finnegan, or hybrid NOWS management frameworks, reducing nursing burden and improving infant stabilization in hospital NICU and maternity settings.

Quantifiable outcome

  • Clinically proven to console opioid-exposed newborns as effectively as holding
  • +1 more outcomes

Companies that use Prapela

Customer profile

Segments1 record

Ideal customer profiles1 record

Prapela technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Prapela partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Prapela competitors and assessment

Company assessment

Broad incumbents

  • Masimo: Medical technology company with neonatal pulse oximetry and patient monitoring products sold into hospital NICUs. Comparable in regulatory-cleared, evidence-based neonatal device sales, though focused on monitoring rather than soothing.
  • Natus Medical: Established medical device company with a broad neonatal and neurology product portfolio, including NICU screening and monitoring devices. Overlaps with Prapela in serving hospital neonatal units and pursuing regulatory-cleared devices for newborn care.
  • Drägerwerk: Global manufacturer of NICU incubators, warmers, and neonatal respiratory care equipment. Comparable as a hospital-channel medical device vendor addressing neonatal intensive care workflows, though Prapela operates in a far more focused niche.
  • Fisher & Paykel Healthcare: Listed respiratory and neonatal care device company selling infant warming, CPAP, and humidification products into NICUs worldwide. Comparable hospital sales motion and regulatory pathway, but much broader product portfolio.
  • GE HealthCare: Large incumbent selling NICU incubators, warmers, and patient monitoring into hospitals globally. Comparable as a hospital-channel neonatal device vendor with established GPO contracts.
  • Philips (Mother & Child Care): Major healthcare technology vendor with neonatal monitoring, warming, and NICU informatics offerings. Comparable as a NICU capital equipment competitor with established hospital procurement relationships.

Regional players

  • Atom Medical Corporation: Japanese manufacturer specializing in neonatal and obstetric medical equipment, including incubators and bassinets. Comparable as a focused neonatal medical device vendor, though primarily serving Asia-Pacific markets.

Emerging players

  • Phoenix Medical Systems: Manufacturer of neonatal and infant care equipment (incubators, bassinets, phototherapy). Comparable as a focused neonatal medical device maker targeting hospital customers.
  • Inspirational Healthcare (SLE/Inspiration Healthcare): Specialist neonatal medical device company selling ventilators and infant care equipment into NICUs. Comparable as a focused neonatal device vendor with similar hospital sales motion.
  • Medela: Company with neonatal and NICU product lines including feeding support and breast milk solutions sold into hospitals. Partial overlap in NICU channel and newborn care category, though focused on feeding rather than soothing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Prapela social profiles

Digital presence

Prapela compliance and trust

Trust signal

Compliance1 record

Prapela financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prapela leadership team

Management profile

Number of profiles

Profiles3 records

Prapela funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prapela M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prapela

What does Prapela do?

Prapela develops and sells the SVS Bassinet Pad, an FDA De Novo authorized medical device that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns and infants with Neonatal Abstinence Syndrome (NOWS). The device operates continuously alongside clinical care teams to stabilize drug-exposed infants as effectively as human holding, while reducing nursing workload in hospital NICU and maternity settings.

Is Prapela a public or private company?

Prapela is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Prapela founded?

Prapela was founded in 2017. It employs 1 to 10 people.

Where is Prapela based?

Prapela is headquartered in Portland, United States, in the North America region.

How does Prapela make money?

One revenue line is on record: SVS Bassinet Pad Device Sales.

Who are Prapela's main competitors?

Broad incumbents on record are Masimo, Natus Medical, Drägerwerk, Fisher & Paykel Healthcare, GE HealthCare and Philips (Mother & Child Care). Atom Medical Corporation is listed as a regional player. Emerging players are Phoenix Medical Systems, Inspirational Healthcare (SLE/Inspiration Healthcare) and Medela.

Does Prapela have an API?

No public API is recorded for Prapela.

What industry is Prapela in?

Prapela's product category is Neonatal Medical Devices. Its primary akta.pro industry code is HLAFAJAE, Neonatal Intensive Care & Special Care Nurseries (NICU/SCN). Its NAICS code is 339113 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Harvard GazettePrapela: from understanding infant breathing rhythms to treating newborn babiesResearchers at the Wyss Institute, led by David Paydarfar, used NIH funding to study infant breathing rhythms and develop a vibrating mattress pad to prevent apnea of prematurity and neonatal opioid withdrawal syndrome. The device received FDA De Novo clearance in 2025 for treating opioid-exposed newborns, and the team continues to seek SBIR funding.FierceBiotechFDA clears vibrating mattress pad to stimulate breathing in premature newbornsThe FDA granted de novo clearance to Prapela's vibrating mattress pad for hospital bassinets, designed to stimulate rhythmic breathing in premature newborns. The device has been studied for apnea of prematurity and opioid-exposed newborns, with a trial showing fewer treatment days and lower morphine doses. Prapela estimates apnea affects 1.6 million newborns annually, costing $17 billion.AASMFDA clears hospital bassinet pad for newbornsThe FDA granted De Novo clearance to the Prapela SVS hospital bassinet pad on April 4. The device delivers stochastic vibrotactile stimulation to help newborns with neonatal opioid withdrawal syndrome, and a JAMA Pediatrics trial showed it reduced treatment days and morphine doses.ConsonanceTop 10 Neonatology Startups with Cutting-Edge Medical DevicesAn article lists ten neonatology startups developing medical devices for premature infants, including Amnion Life's AmnioBed incubator, Prapela's vibration-assisted breathing device, PediaFeed's feeding tube, and Bambi Medical's wireless vital sign monitor. The piece notes that several devices are not yet commercially available and await certification.CharleshoodfoundationPrapela – The Charles Hood FoundationThe Charles Hood Foundation is providing program-related investment support to Prapela for the development of a next-generation baby box utilizing Stochastic Vibro-tactile Stimulation (SVS) technology. This clinically-validated solution, developed in collaboration with Harvard’s Wyss Institute and various medical centers, aims to treat neonatal abstinence syndrome and other infant health issues. The initiative addresses a high-priority pediatric health problem affecting an estimated 50,000 infants annually in the United States.PR NewswirePRAPELA RECEIVES FDA'S BREAKTHROUGH DEVICE DESIGNATION TO INVESTIGATE THE USE OF STIMULATION TO TREAT APNEA OF PREMATURITYPrapela, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its proprietary stimulation mattress pad to treat apnea of prematurity (AOP) in preterm newborns, potentially accelerating the device's path to market. The vibration-based stimulation pad, placed inside incubators or radiant warmers, delivers stochastic stimulation to improve respiratory rhythm without requiring wires or leads connected to infants. Prapela is collaborating with Tufts Medical Center and the University of Alabama at Birmingham to complete clinical trials, with the goal of introducing the first new AOP treatment in over twenty years to address a condition that costs the U.S. more than $17 billion annually.PrwebImpact Pediatric Health Announces Results of Startup Pitch Competition at SXSW 2019Impact Pediatric Health announced the winners of its fifth annual pitch competition at SXSW 2019, awarding four pediatric device startups $25,000 each. The recipients include Smileyscope, Bardy Diagnostics, Prapela, and PolyVascular, with PolyVascular also winning a Health Disparities and Equity award.PR NewswireWyss Institute's infant health-promoting technology licensed to PrapelaHarvard University's Wyss Institute has licensed its clinically validated Stochastic Vibro-tactile Stimulation (SVS) technology to startup Prapela Inc. for commercialization, following a licensing agreement through Harvard's Office of Technology Development. The SVS technology, developed in collaboration with researchers from University of Massachusetts Medical School, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, uses subtle random vibratory stimulation to improve cardiorespiratory stability in infants suffering from apnea of prematurity, neonatal abstinence syndrome, and other conditions. Prapela plans to develop an SVS hospital bassinet pad and next-generation baby box device, having received funding from the Charles H. Hood Foundation and awards from Johnson & Johnson and Children's National Health System.PR Newswire$250K awarded to six winners presenting innovative pediatric medical devicesSix companies won a total of $250,000 in awards at the Fifth Annual Pediatric Device Innovation Symposium, with four companies receiving $50,000 each and two receiving $25,000. The competition, organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System and sponsored by the NCC-PDI (an FDA-funded consortium led by Children's National and the University of Maryland), selected winners from a record 98 submissions from five countries. The awardees—CorInnova, Green Sun Medical, Hub Hygiene/Georgia Institute of Technology, NAVi Medical Technologies, Prapela LLC, and X-Biomedical Inc.—focus on pediatric medical devices including cardiac assistance, spinal correction, infection prevention, and surgical tools.